ArticleFrontiers in endocrinology2026
Catamenial diabetic ketoacidosis in a rural area of Kananga, Democratic Republic of the Congo: a case report.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic ketoacidosis (DKA) is a life-threatening acute complication of diabetes mellitus most commonly triggered by infection, metabolic stress, or inadequate insulin therapy. We report an unusual case of a young woman with type 1 diabetes who experienced recurrent episodes of ketoacidosis during the premenstrual period, suggesting a catamenial form of DKA. This case highlights the importance of considering hormonal fluctuations related to the menstrual cycle in diabetes management and in identifying factors of imbalance. The patient presented with abdominal pain, severe fatigue, and polyuria-polydipsia, with a blood glucose level of 560 mg/dL, beta-hydroxybuturate of 3.6 mmol/L, potassium of 2.4 mmol/L and pH of 7.24. Inflammatory markers were absent and no usual precipitating factors were identified. Management included intravenous insulin therapy, rehydration, potassium supplementation, and transition to basal-bolus insulin. Part of the serum was sent to France for diabetes typing, confirming type 1 diabetes and additional assays. The patient reported that these episodes occurred 3 to 4 days before menstruation. This case underscores the need to consider hormonal fluctuations related to the menstrual cycle in diabetes management, particularly in a resource-limited settings, to adjust insulin strategies and prevent serious complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.